Cancer startup GO Therapeutics signs $195m licensing deal with Roche

08:20 EDT 3 Oct 2018 | Pharmaceutical Business Review

As per terms of the deal, Roche will secure worldwide and exclusive license from GO Therapeutics for cancer-specific targeting antibodies. The license will allow Roche to develop and

The post Cancer startup GO Therapeutics signs $195m licensing deal with Roche appeared first on Pharma Business review.

Original Article: Cancer startup GO Therapeutics signs $195m licensing deal with Roche

More From BioPortfolio on "Cancer startup GO Therapeutics signs $195m licensing deal with Roche"